Introduction
Social Security Institution reimbursement rules for pharmacies in Turkey are one of the most important legal and financial issues affecting pharmacy practice. In Turkey, pharmacies do not operate only under general pharmacy law and Ministry of Health regulations. They also work within a comprehensive reimbursement system administered by the Social Security Institution, known in Turkish as Sosyal Güvenlik Kurumu or SGK.
For many pharmacies, SGK-covered prescriptions constitute a substantial part of daily business. This means that a pharmacy’s financial stability depends not only on selling medicines lawfully, but also on submitting prescriptions, reports, electronic records and reimbursement claims in full compliance with SGK rules. A prescription may be medically valid and lawfully dispensed, but SGK may still reject or deduct payment if reimbursement conditions are not met.
The legal framework is mainly based on Law No. 5510 on Social Insurance and General Health Insurance, the Health Implementation Communiqué, known as Sağlık Uygulama Tebliği or SUT, the SGK–TEB pharmacy protocol, MEDULA pharmacy system rules, reimbursable medicine lists, SGK announcements and audit practice. SGK’s own 2026 reimbursement announcements refer to changes made under Law No. 5510, the SGK Drug Reimbursement Regulation and SUT provisions concerning the Bedeli Ödenecek İlaçlar Listesi, also known as EK-4/A.
Therefore, SGK reimbursement compliance is a separate legal discipline within Turkish pharmacy law. It requires constant monitoring of SUT amendments, medicine list updates, diagnosis and report conditions, prescription restrictions, patient eligibility, MEDULA entries, pharmacy protocol obligations, invoice submission rules and audit risks.
The Role of SGK in Pharmacy Reimbursement
SGK is the public institution responsible for administering social security and general health insurance coverage in Turkey. In pharmacy practice, SGK determines which medicines may be reimbursed, under what conditions, for which patients, with which medical reports, by which physicians, in what quantities and through which electronic systems.
This reimbursement system is not static. SGK regularly publishes updates concerning SUT amendments and reimbursable medicine lists. For example, SGK announced a SUT amendment published in the Official Gazette dated 23 May 2026 and attached an updated EK-4A Bedeli Ödenecek İlaçlar Listesi together with the SUT amendment document. SGK also continues to publish periodic “Bedeli Ödenecek İlaçlar Listesinde Yapılan Düzenlemeler” announcements; the 24 June 2026 announcement was published as “Duyuru 2026/24.”
For pharmacies, this means that reimbursement compliance cannot be based on old printed rules or informal market practice. A pharmacy must follow current SGK announcements, MEDULA updates and SUT amendments. A rule that was valid in a previous period may change, and a medicine that was reimbursable under certain conditions may later be added, removed, activated, restricted or modified.
Difference Between Legal Sale and SGK Reimbursement
One of the most important distinctions in Turkish pharmacy practice is the difference between legal sale and SGK reimbursement. A medicine may be lawfully sold by a pharmacy under pharmacy law, but that does not automatically mean SGK must reimburse it.
For example, a medicine may require a prescription under pharmacy legislation. If the patient has a valid prescription, the pharmacy may be legally allowed to dispense it. However, SGK reimbursement may additionally require a specialist physician report, a diagnosis code, prior treatment history, laboratory values, patient age criteria, dose limits, treatment duration limits or inclusion in EK-4/A.
This distinction is critical in disputes. A patient may say, “I have a prescription, so SGK must pay.” A pharmacist may say, “The medicine is legal, so SGK should reimburse it.” However, SGK applies reimbursement rules, not only pharmacy dispensing rules. Therefore, pharmacy compliance must be evaluated under both pharmacy law and SGK reimbursement law.
SUT: Health Implementation Communiqué
The Health Implementation Communiqué, known as SUT, is the core regulatory document for SGK healthcare reimbursement. In pharmacy practice, SUT determines prescription conditions, medicine reimbursement criteria, report requirements, dosage limits, treatment protocols, physician specialty rules, patient eligibility conditions and payment principles.
SUT is frequently amended. SGK’s 2026 announcements show that amendments to SUT and the reimbursable medicine list are published through official SGK channels and may include updated Excel lists and amendment documents. This is especially important for pharmacies because reimbursement errors often arise from outdated SUT knowledge.
A pharmacy should therefore build its workflow around current SUT rules. Before submitting a reimbursable prescription, the pharmacy should check whether the medicine is included in the relevant list, whether the prescription meets SUT conditions, whether the report is valid, whether the prescribing physician is authorized, whether the patient’s diagnosis matches the reimbursement rule and whether quantity limits are respected.
EK-4/A: Bedeli Ödenecek İlaçlar Listesi
The EK-4/A Bedeli Ödenecek İlaçlar Listesi is the reimbursable medicines list used in SGK practice. If a medicine is not included in the relevant reimbursable list or does not satisfy the listed conditions, SGK may refuse payment even if the medicine was lawfully dispensed.
SGK regularly announces changes to the reimbursable medicine list. The 2026/7 SGK announcement states that changes to the list were made under Law No. 5510, the SGK Drug Reimbursement Regulation and SUT article 4.4.1, and the announcement listed categories such as medicines added to EK-4/A, medicines amended in EK-4/A, medicines activated in EK-4/A and medicines removed from EK-4/A.
This shows that EK-4/A is dynamic. Pharmacies must check whether a product is newly added, removed, activated, restricted or amended. A pharmacy that relies on an old version of the list may submit claims incorrectly and face deductions.
SGK–TEB Pharmacy Protocol
A pharmacy’s relationship with SGK is also governed by the protocol between SGK and the Turkish Pharmacists’ Association, known as Türk Eczacıları Birliği or TEB. SGK announced that the protocol concerning medicine supply from TEB-member pharmacies to persons covered by SGK was signed in March 2026. The SGK announcement stated that the agreement included improvements to sales revenue brackets and prescription service fees.
The SGK–TEB protocol is important because it regulates the contractual framework under which pharmacies provide medicines to SGK beneficiaries. It may address pharmacy discounts, service fees, invoice procedures, prescription submission, audit rules, sanctions, deductions, special prescription categories and operational obligations.
The protocol may also be amended through additional protocols. For example, the 2026/2 additional protocol amended a protocol annex by adding the active substance migalastat after certain listed active substances and stated that the additional protocol would apply after MEDULA system arrangements. This demonstrates that the protocol framework is not fixed; pharmacies must monitor protocol updates as well as SUT updates.
MEDULA Pharmacy System
The MEDULA pharmacy system is the electronic infrastructure through which pharmacies process SGK-covered prescriptions and reimbursement claims. In practice, MEDULA is not merely a technical system. It is the operational gatekeeper of reimbursement.
A pharmacy must enter prescription data correctly, verify patient eligibility, submit required information, check system warnings, process reports and comply with SGK rules reflected in the system. However, pharmacy compliance cannot be reduced to “MEDULA accepted it.” A system acceptance may not always eliminate audit risk. SGK may later review whether the prescription, report, diagnosis, physician specialty or medicine quantity actually complied with SUT and protocol rules.
Therefore, pharmacies should treat MEDULA as a tool, not as a complete legal guarantee. The pharmacist must still apply legal judgment, keep supporting documents, verify medical reports and preserve evidence for possible SGK audits.
Prescription Compliance in SGK Reimbursement
Prescription compliance is one of the most important reimbursement conditions. SGK-covered prescriptions must generally satisfy all formal and substantive requirements. These may include patient information, physician information, diagnosis, medicine details, dosage, prescription date, report reference and electronic system compatibility.
Errors that may cause SGK reimbursement problems include missing diagnosis, wrong diagnosis code, expired report, wrong physician specialty, excessive quantity, medicine outside report indication, repeated prescription before permitted time, incorrect patient eligibility, incorrect MEDULA entry and mismatch between prescription and dispensed product.
From a legal perspective, the pharmacy must not only supply medicine but also document that the supply was reimbursable. If SGK later applies a deduction, the pharmacy may need to prove that the prescription met the applicable SUT and protocol conditions at the time of supply.
Medical Report Requirements
Many medicines require medical reports for SGK reimbursement. These reports may need to be issued by specific hospitals, medical boards, specialist physicians or authorized healthcare providers. The report may also need to include diagnosis, treatment duration, medicine name, dosage, clinical justification and other required elements.
A valid report under medical practice may still be insufficient for SGK reimbursement if it does not satisfy SUT criteria. For example, the report may be expired, issued by an unauthorized physician, missing required diagnosis language or inconsistent with the medicine’s reimbursement indication.
Pharmacies should therefore review reports carefully before processing expensive, chronic, specialty or restricted medicines. The higher the medicine cost, the greater the financial risk of reimbursement rejection. In practice, many SGK deductions arise not because the medicine was never used by the patient, but because the report or prescription did not exactly meet reimbursement conditions.
Reimbursement of Specialty and High-Cost Medicines
High-cost medicines, rare disease treatments, biological products, oncology medicines, enzyme replacement therapies and specialty drugs often carry stricter reimbursement requirements. The SGK–TEB protocol and additional protocols may contain annexes and special rules for certain active substances or prescription groups.
The 2026/2 additional protocol concerning medicine supply from TEB-member pharmacies to SGK-covered persons specifically amended a protocol annex by adding migalastat to a list that already included active substances such as agalsidase alfa, agalsidase beta, idursulfase, imiglucerase, laronidase, taliglucerase alfa and velaglucerase alfa. These types of amendments show that SGK reimbursement for specialty medicines is closely regulated and may change by active substance, protocol annex and MEDULA system arrangement.
Pharmacies dispensing high-cost medicines should apply enhanced compliance controls. A single rejected prescription may create a major financial loss. The pharmacy should confirm reimbursement status, report validity, patient eligibility, prescribing authority, dose limits and protocol-specific rules before supplying such medicines.
Patient Eligibility and Coverage
SGK reimbursement depends not only on the medicine and prescription but also on the patient’s coverage status. The patient must be covered under the relevant SGK scheme, and the medicine must be reimbursable for that patient under the applicable rules.
Issues may arise where the patient’s insurance status is suspended, contribution debt affects eligibility, coverage category changes, the patient has private or foreign insurance complications, or the prescription is processed under an incorrect patient category. MEDULA usually helps identify eligibility, but pharmacies should still be careful with exceptional cases.
In practice, patient eligibility problems can lead to payment rejection or patient disputes. Pharmacies should explain to patients that SGK reimbursement is subject to system approval and legal criteria, not merely possession of a prescription.
Co-Payments, Patient Contributions and Price Differences
SGK reimbursement does not always mean that the patient pays nothing. Depending on the medicine, patient status, reference price, equivalent medicine rules and reimbursement conditions, patients may need to pay contribution amounts, price differences or non-covered portions.
Pharmacies must handle these amounts transparently. Patient disputes often arise when the patient believes the medicine should be fully covered, while the pharmacy requests a difference based on SGK reimbursement rules. The pharmacist should be able to explain that SGK reimbursement may cover only part of the medicine cost and that certain differences arise from official pricing and reimbursement mechanisms.
From a legal risk perspective, pharmacies should ensure that amounts collected from patients are consistent with SGK and pricing rules. Incorrect collection may cause complaints, audit findings or consumer disputes.
Equivalent Medicine and Reference Pricing Issues
SGK reimbursement practice may involve equivalent medicine groups and reference pricing principles. Where SGK reimburses up to a certain reference amount, the patient may need to pay a price difference if a more expensive equivalent is selected. Pharmacies must therefore understand the relationship between prescribed medicine, equivalent products, patient preference, physician restrictions and SGK reimbursement limits.
In disputes, the patient may claim that the pharmacy charged an unlawful difference. The pharmacy’s defense will depend on whether the difference was calculated under SGK rules, whether the patient was properly informed and whether the medicine supplied was consistent with the prescription and reimbursement system.
A strong pharmacy compliance system should include staff training on equivalent medicines, patient explanations, system outputs and record preservation.
Invoice and Prescription Submission Procedures
SGK reimbursement requires proper submission of prescriptions, invoices and supporting documentation. Even if the prescription itself is reimbursable, a pharmacy may face payment delays or deductions if submission procedures are not followed.
Common procedural issues include late submission, missing prescription documents, missing report copies, inconsistent invoice totals, system-document mismatch, incorrect prescription grouping, missing signatures where required, unreadable documents and failure to respond to SGK requests.
Pharmacies should create a monthly reimbursement control process. Before submitting invoices and prescription files, the pharmacy should review high-risk prescriptions, check report validity, confirm MEDULA entries, verify physical documents and ensure that all files are organized. A small administrative mistake may create significant cumulative deductions.
SGK Audits and Pharmacy Deductions
SGK may audit pharmacy claims and apply deductions where it finds non-compliance. These deductions may arise from substantive or procedural violations. Substantive violations involve situations where the medicine did not meet reimbursement conditions. Procedural violations involve documentation, submission or system errors.
Examples include dispensing medicine before report validity, exceeding quantity limits, using wrong diagnosis code, processing prescriptions contrary to SUT rules, missing required physician specialty, reporting mismatch, incorrect MEDULA entry, unauthorized repeat prescription, non-compliant specialty medicine supply and absence of required supporting documents.
Pharmacies should treat SGK deductions as legal disputes, not merely accounting problems. Each deduction should be reviewed with the relevant SUT provision, protocol article, prescription record, report, MEDULA output and patient file. Where the deduction is incorrect or disproportionate, the pharmacy may submit an objection or pursue available remedies.
Legal Remedies Against SGK Deductions
When SGK applies a reimbursement deduction, the pharmacy should first identify the legal basis of the deduction. It should obtain the audit finding, review the prescription file, compare the transaction date with the SUT and protocol rules in force at that time, and determine whether the deduction is factually and legally justified.
A strong objection should include the prescription, medical report, MEDULA record, invoice, patient eligibility record, physician information, relevant SUT provision, protocol provision and any SGK announcement applicable at the date of dispensing. Timing is especially important because reimbursement rules change frequently. The pharmacy should not rely on current rules if the prescription was dispensed under a previous rule, or vice versa.
If administrative objection does not resolve the dispute, judicial remedies may be considered depending on the nature of the deduction and contractual relationship. Because deadlines and jurisdiction may vary according to the specific dispute, legal review should be conducted promptly.
Relationship Between SGK Rules and Pharmacy Law
SGK reimbursement rules operate alongside general pharmacy law. A pharmacy must comply with both. General pharmacy law governs licensing, pharmacist responsibility, prescription-only medicine supply, storage, controlled medicines, record-keeping and professional ethics. SGK rules govern whether SGK will pay for a medicine supplied to a covered person.
A pharmacy can violate SGK rules without violating pharmacy law. For example, a prescription may be lawfully dispensed but not reimbursable due to SUT restrictions. Conversely, a pharmacy can violate pharmacy law even if MEDULA processes a claim. For example, if prescription collection or referral rules are violated, general pharmacy law problems may arise independently from reimbursement approval.
Therefore, pharmacy compliance must be two-layered: legal dispensing compliance and reimbursement compliance.
Frequent SGK Reimbursement Mistakes
The first common mistake is assuming that MEDULA approval eliminates all risk. MEDULA approval is important, but SGK may still audit compliance later.
The second mistake is failing to check report validity. Many deductions arise because a report expired, was incomplete or did not match the medicine’s reimbursable indication.
The third mistake is relying on old SUT rules. SGK regularly publishes list changes and SUT amendments, including repeated 2026 updates concerning reimbursable medicine lists.
The fourth mistake is not preserving supporting documents. If a pharmacy cannot prove compliance during audit, it may lose reimbursement even where the medicine was actually supplied.
The fifth mistake is weak staff training. Pharmacy technicians or assistants may process prescriptions, but the pharmacist remains responsible for compliance. High-risk prescriptions should be reviewed by the responsible pharmacist.
Practical Compliance Checklist for Pharmacies
A pharmacy should use a structured SGK reimbursement checklist. First, confirm that the patient is SGK-covered and eligible. Second, check whether the medicine is in EK-4/A and whether any active, removed, amended or restricted status applies. Third, review SUT conditions for diagnosis, physician specialty, medical report, dosage and duration. Fourth, verify prescription formalities and electronic prescription data. Fifth, check whether the medicine is subject to special protocol annexes or MEDULA-specific rules.
Sixth, confirm patient contribution and price difference transparently. Seventh, preserve all supporting documents. Eighth, reconcile MEDULA records with physical documents and invoices. Ninth, review high-cost medicines before delivery. Tenth, monitor SGK announcements and protocol amendments continuously.
This checklist should be applied especially to chronic disease medicines, biological products, oncology medicines, rare disease treatments, imported medicines, high-cost medicines and prescriptions requiring specialist reports.
SGK Reimbursement and Pharmacy Financial Management
SGK reimbursement rules have a direct financial impact on pharmacies. A pharmacy’s cash flow may depend on timely and accurate SGK payments. Reimbursement deductions, delayed payments, rejected prescriptions and audit findings can significantly affect profitability.
The 2026 SGK–TEB protocol announcement noted improvements to sales revenue brackets and prescription service fees, showing that pharmacy economics are partly determined through SGK–TEB negotiations. For this reason, pharmacists should monitor not only medical reimbursement rules but also protocol provisions concerning fees, discounts, service payments and revenue brackets.
A pharmacy should maintain separate financial monitoring for SGK receivables, patient collections, deductions under objection, high-risk prescription exposure and expected reimbursement timelines. Legal compliance and financial management are closely connected in SGK-covered pharmacy practice.
SGK Reimbursement and High-Risk Prescription Review
Not every prescription carries the same risk. Pharmacies should create a high-risk review category. This category may include expensive medicines, medicines recently added or removed from EK-4/A, drugs with active substance restrictions, medicines requiring specialist reports, oncology drugs, biological products, rare disease medicines, foreign-sourced medicines and prescriptions involving unusual dosage or duration.
Before dispensing such medicines, the responsible pharmacist should review the reimbursement conditions personally. This is especially important because a single high-cost deduction may exceed the profit from many ordinary prescriptions.
A legally careful pharmacy should document high-risk checks. Even a short internal note showing report review, SUT condition check and MEDULA confirmation may help in a later dispute.
SGK Announcements and Continuous Monitoring
SGK reimbursement law is highly dynamic. SGK publishes announcements concerning SUT amendments, reimbursable medicine list changes, medicine supply source lists and other operational matters. The SGK General Health Insurance announcements page shows multiple June 2026 updates concerning reimbursable medicine lists, medicine supply source lists and SUT changes.
This continuous change creates a professional duty for pharmacies to monitor official channels. A pharmacy should assign responsibility for following SGK announcements, TEB notices, MEDULA updates and SUT amendments. Staff should be informed when rules change.
In practice, many reimbursement disputes arise because a rule changed but the pharmacy continued using old procedures. Continuous monitoring is therefore a legal risk management tool.
Pharmacy Protocol Violations and Sanctions
Violations of the SGK–TEB pharmacy protocol may lead to deductions, warnings, contractual sanctions, temporary restrictions or other consequences depending on the relevant protocol provision. Protocol violations are different from ordinary administrative sanctions under pharmacy law, but they can be equally damaging financially.
Possible protocol violations may include incorrect prescription processing, document deficiencies, failure to comply with special distribution rules, improper handling of SGK-covered prescriptions, submission irregularities or failure to follow MEDULA and protocol requirements.
When a protocol sanction is imposed, the pharmacy should analyze whether SGK correctly interpreted the protocol, whether the violation actually occurred, whether the sanction is proportionate and whether procedural rights were respected.
Frequently Asked Questions
What is SGK reimbursement for pharmacies in Turkey?
SGK reimbursement is the system through which pharmacies supply medicines to SGK-covered persons and receive payment from the Social Security Institution under SUT, MEDULA and the SGK–TEB pharmacy protocol.
What is SUT?
SUT, or Sağlık Uygulama Tebliği, is the Health Implementation Communiqué that sets reimbursement conditions for healthcare services and medicines, including prescription, report, diagnosis and payment rules. SGK regularly publishes SUT amendments and updated reimbursable medicine lists.
What is EK-4/A?
EK-4/A is the list of medicines reimbursed by SGK. SGK announcements show that medicines may be added, amended, activated or removed from this list.
Does MEDULA approval guarantee payment?
Not always. MEDULA approval is important, but SGK may later audit the prescription and apply deductions if SUT, protocol or documentation rules were not met.
What should a pharmacy do if SGK applies a deduction?
The pharmacy should review the deduction reason, prescription file, medical report, MEDULA records, SUT provisions, protocol rules and SGK announcements applicable at the dispensing date. If the deduction is incorrect, the pharmacy should submit a timely objection with supporting documents.
Conclusion
Social Security Institution reimbursement rules for pharmacies in Turkey are a crucial part of pharmacy law and pharmacy financial management. SGK reimbursement is governed by SUT, EK-4/A reimbursable medicine lists, MEDULA pharmacy system rules, SGK–TEB pharmacy protocol provisions and frequent SGK announcements.
For pharmacies, the key point is that lawful medicine dispensing and SGK reimbursement are not identical. A medicine may be legally dispensed but not reimbursable if SGK conditions are not met. Therefore, pharmacies must check patient eligibility, medicine list status, report validity, diagnosis requirements, physician authority, dosage limits, MEDULA entries and documentation rules before submitting reimbursement claims.
The reimbursement system is dynamic. SGK continues to publish SUT amendments, EK-4/A updates and protocol-related announcements. Pharmacies that fail to monitor these changes may face deductions, delayed payments, audit findings and legal disputes.
A legally secure pharmacy should build a preventive SGK compliance system. This means staff training, high-risk prescription review, document preservation, MEDULA control, monthly invoice review, announcement monitoring and timely objection to unjustified deductions.
In Turkey, SGK reimbursement compliance is not merely an accounting task. It is a legal obligation, a financial risk area and a core element of sustainable pharmacy operation. A pharmacy that understands and properly applies SGK reimbursement rules can reduce audit exposure, protect cash flow, avoid unnecessary disputes and provide safer, more reliable service to SGK-covered patients.
Yanıt yok